Non-Metastatic castration-resistant prostate cancer / non-metastatic biochemical recurrence US/Europe/Asia Phase-III Breast cancer US/Europe Phase-II / receptor antagonist Irritable bowel syndrome / nephropathy Oral In-house ASP3700 Osteoarthritis Oral In-house AGS67E Cancer / C receptor agonist ASP7373 Influenza / certolizumab pegol PEGylated anti-tumor necrosis factor-alpha antibody Disease / III Oral AstraZeneca New indication New formulation Hyperphosphatemia / Japan Bioequivalence study Oral GnRH antagonist Prostate cancer / disease / castration-resistant prostate cancer / urinary incontinence / roxadustat HIF stabilizer Anemia / Chronic / difficile infection / ASP9226 Neuropathic pain Oral In-house ASP3662 Alzheimer’s disease Oral In-house ASG-15ME Cancer / metastatic castration-resistant prostate cancer / Area / Phase ASP3652 Bladder pain syndrome / Oral In-house Infectious enteritis / pain / chronic kidney disease / Phase-l Target Disease Dosage Form Origin Cancer / sodium Prostacyclin receptor stimulator Chronic / Area / Phase Irritable bowel syndrome / diarrhea / Area / Phase Dosage Form Origin ASP7374 Influenza / renal failure / prostate cancer / hematopoietic cell transplant recipients US/Europe/Japan Phase-III Cytomegalovirus infection / idiopathic overactive bladder / ASG-22ME Cancer / ASP8273 Cancer Oral In-house ASP7962 Osteoarthritis / Area / Phase Dosage Form Origin Remarks Invasive aspergillosis / nephrosclerosis / /
MedicalTreatment
chemotherapy / organ transplant / dialysis / /
Organization
FDA / /
Product
H5N1 influenza Japan Phase-II Injection / Japan Phase-III Injection / US Phase-II Japan Phase-I Injection / Invasive candidiasis US Phase-III Injection / Europe Phase-II Dosage Form Origin Injection / nateglinide / Osteoporosis Japan Phase-III Injection / Hyperlipidemia Japan Phase-III Injection / Gastric cancer Japan Phase-III Injection / in / /